Delivery Order SPE2DB24D2003-SPE2DB25FXMT6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) valued at $11,242.25. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 8, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. The contract is valued at $58,587.97 and utilizes firm fixed pricing with no set-aside designation, indicating the award was made through open competition. Performance will take place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of September 11, 2025. This...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a $3,700.62 delivery order by the Defense Logistics Agency on September 17, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count unit dose packages). The contract represents a firm fixed-price, non-competitive set-aside delivery order with an ultimate completion date of September 18, 2025. This award was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a $17,638.89 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive award status. The contract is set to complete on August 12, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $16.1K delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on September 11, 2025, with completion scheduled for September 12, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The work will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $18,491.04 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This competitively awarded, firm fixed-price contract is a non-set-aside procurement with an ultimate completion date of August 18, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and...
- The Defense Logistics Agency awarded a $18,669.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $25,189.80 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract carries no set-aside designation and...
- The Defense Logistics Agency awarded a delivery order valued at $3,578.79 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose) on September 9, 2025, with completion expected by September 10, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be...
- The Defense Logistics Agency awarded a $46,037.03 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. The contract is non-competitive with no set-aside designation and carries an ultimate completion date of July 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXMT6Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) valued at $37,258.50. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The contract is set to conclude on September 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a JAK inhibitor used primarily for rheumatoid arthritis treatment, reflecting the Defense Logistics Agency Medical Supply Chain's procurement of specialized pharmaceutical products for military and veteran healthcare systems. This delivery order represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999.9 million through December 2026. This prime indefinite delivery vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs, including the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. AmerisourceBergen's federal contract portfolio demonstrates significant capability in fulfilling diverse pharmaceutical procurement requirements across multiple therapeutic domains, positioning it as a critical vendor within the Defense Logistics Agency's medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $37.3k | 9/16/25 |